Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enavogliflozin monotherapy in type 2 diabetes
NCT04632862Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enavogliflozin in type 2 diabetes mellitus (T2DM), sponsored by Daewoong Pharmaceutical. Started Nov 2020; status: completed.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04632862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04632862.